To the full analysis
Buyback calculator for Travere Therapeutics
Travere Therapeutics stock: key metrics
TVTXTravere Therapeutics had an operating margin of −12.8% and a return on invested capital (ROIC) of −47.1% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2008 | no data | no data | no data |
| 2011 | no data | no data | no data |
| 2012 | no data | no data | no data |
| 2013 | no data | no data | no data |
| 2014 | 98.0% | −283.0% | −393.4% |
| 2015 | 97.8% | −50.8% | 117.4% |
| 2016 | 96.6% | −43.6% | −35.9% |
| 2017 | 97.7% | −34.7% | −38.6% |
| 2018 | 96.6% | −48.7% | −62.5% |
| 2019 | 97.0% | −56.9% | −83.5% |
| 2020 | 96.9% | −88.8% | −85.4% |
| 2021 | 97.1% | −151.3% | no data |
| 2022 | 96.0% | −292.2% | −254.4% |
| 2023 | 92.1% | −267.2% | no data |
| 2024 | 96.7% | −138.9% | −137.9% |
| 2025 | 97.9% | −12.8% | no data |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2008 | 0.0% | no data | −100.0% |
| 2011 | 23.5% | no data | −100.0% |
| 2012 | 200.0% | no data | −100.0% |
| 2013 | 184.7% | no data | −100.0% |
| 2014 | 200.0% | no data | −81.9% |
| 2015 | 39.1% | −76.3% | 22.9% |
| 2016 | −15.6% | −43.7% | −9.1% |
| 2017 | −20.4% | −63.5% | −11.5% |
| 2018 | −32.3% | −11.9% | −14.5% |
| 2019 | −66.2% | −13.8% | −24.2% |
| 2020 | −80.2% | −27.1% | −27.9% |
| 2021 | no data | −27.0% | no data |
| 2022 | −100.0% | −42.7% | −41.4% |
| 2023 | no data | −53.7% | no data |
| 2024 | −100.0% | −47.7% | −54.1% |
| 2025 | no data | −47.1% | no data |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026, previously Weak
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.